Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Depreciation & Amortization (CF) (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Depreciation & Amortization (CF) data on record, last reported at $6.1 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) changed 0.3% year-over-year to $6.1 million; the TTM value through Dec 2025 reached $24.2 million, up 2.6%, while the annual FY2025 figure was $24.2 million, 2.6% up from the prior year.
  • Depreciation & Amortization (CF) reached $6.1 million in Q4 2025 per MIRM's latest filing, roughly flat from $6.1 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $6.1 million in Q4 2025 and bottomed at $79000.0 in Q2 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $3.1 million, with a median of $2.0 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 1204.76% in 2022, then rose 0.12% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $342000.0 in 2021, then surged by 251.17% to $1.2 million in 2022, then soared by 357.45% to $5.5 million in 2023, then rose by 10.23% to $6.1 million in 2024, then grew by 0.3% to $6.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $6.1 million in Q4 2025, $6.1 million in Q3 2025, and $6.1 million in Q2 2025.